Lyka Labs Limited

Equities

LYKALABS

INE933A01014

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:48 2024-05-03 am EDT 5-day change 1st Jan Change
118.8 INR -2.82% Intraday chart for Lyka Labs Limited -3.57% -4.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lyka Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Lyka Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Lyka Labs Gets Indian Regulator's Nod to Market Tofacitinib Ointment MT
Lyka Labs Limited Receives Product Permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w CI
Lyka Labs Limited Announces Cessation of Sandeep Parikh as Independent Director CI
Lyka Labs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Lyka Labs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Lyka Labs Limited announced that it has received INR 453.375 million in funding from Ipca Laboratories Limited CI
Lyka Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Lyka Labs Limited announced that it expects to receive INR 453.375 million in funding from Ipca Laboratories Limited CI
Lyka Labs Limited completed the acquisition of Animal Healthcare Business from Agilis Healthcare Pvt. Ltd. for INR 32.5 million. CI
Lyka Labs to Acquire Agilis' Animal Healthcare Business MT
Lyka Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Lyka Labs Limited agreed to acquire Animal Healthcare Business from Agilis Healthcare Pvt. Ltd. for INR 35 million. CI
Chart Lyka Labs Limited
More charts
Lyka Labs Limited is an India-based company that is engaged in the business of pharmaceutical and related activities, including research. The Company is focused on lyophilization - formulations/bulk sterile active pharmaceutical ingredients (APIs), and new product development including novel drug delivery systems in both topical preparation and lyophilized products. The Company manufactures pharmaceutical products, such as dry powder, liquid injections, lyophilized injections, ointment/creams and lotions, and external preparations for several international markets and the domestic market. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, anti-fungal, anti-malarial, anti-bacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
More about the company
  1. Stock Market
  2. Equities
  3. LYKALABS Stock
  4. News Lyka Labs Limited
  5. Lyka Labs Gets Indian Regulator's Nod to Market Tofacitinib Ointment